aminopterin has been researched along with Colorectal Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Evande, RE; Grem, JL; Kos, ME; Meza, JL; Schwarz, JK | 1 |
| Abbruzzeese, J; Berghorn, E; Hausheer, F; Hoff, PM; Hutto, T; Johansen, M; Madden, T; Newman, RA; Ni, D; Zukowski, T | 1 |
| Clamon, GH; Dreicer, R; Hohl, RJ; Riggs, CE | 1 |
3 trial(s) available for aminopterin and Colorectal Neoplasms
| Article | Year |
|---|---|
A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorouracil; Folic Acid Antagonists; Gastrointestinal Neoplasms; Humans; Incidence; Male; Middle Aged; Mucositis; Pancreatic Neoplasms; Polymorphism, Genetic; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase; Time Factors; Treatment Outcome | 2015 |
Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Aminopterin; Colorectal Neoplasms; Female; Folic Acid Antagonists; Humans; Male; Maximum Tolerated Dose; Methotrexate; Middle Aged | 2004 |
Phase II trial of edatrexate in patients with metastatic colorectal cancer.
Topics: Aged; Aminopterin; Antineoplastic Agents; Colorectal Neoplasms; Female; Humans; Male; Middle Aged | 1996 |